CAMP Form 3: Dr. Tardiff Discloses 74,578 Stock Options

Rhea-AI Filing Summary

Initial Form 3 filing shows Dr. Daniel Tardiff, Chief Scientific Officer and director at Camp4 Therapeutics (CAMP), reporting ownership entirely through stock options. He holds options covering 74,578 shares of common stock with exercise prices of $9.08, $3.86, and $3.53. Vesting schedules start on 09/18/2023 and 04/01/2025

Positive

• Substantial option holdings: 74,578 options align officer incentives with shareholders
• Clear vesting schedules: 25% cliff and monthly vesting provide retention alignment

Negative

• No reported direct common stock ownership: economic exposure depends on exercising options
• Exercise prices vary: portions priced at $9.08 may be out-of-the-money depending on market price

Insights

Corporate Governance Analyst

Officer reports only option-based ownership totaling 74,578 shares.

The reporting shows no direct common stock holdings; all beneficial ownership is via four stock options with exercise prices of $9.08, $3.86, and $3.53. Vesting schedules include initial 25% cliffs and monthly vesting thereafter beginning on 09/18/2023 and a separate four-year monthly vesting from 04/01/2025.

Key dependencies are option exercise decisions and timing; dilution and insider alignment will materialize only if options are exercised. Monitor outstanding option counts and any subsequent Form 4s within the next 12 months for exercises or sales.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tardiff Daniel

(Last) (First) (Middle)

ONE KENDALL SQUARE

BLDG 1400 WEST, 3RD FLOOR

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2025

3. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	09/28/2033	Common Stock	22,289	$9.08	D
Stock Option (Right to Buy)	(2)	12/13/2033	Common Stock	22,289	$9.08	D
Stock Option (Right to Buy)	(3)	03/31/2035	Common Stock	25,000	$3.86	D
Stock Option (Right to Buy)	(3)	04/01/2035	Common Stock	5,000	$3.53	D

Explanation of Responses:

1. The option has a vesting start date of September 18, 2023. The shares underlying the option vested with respect to 25% of the shares on the first anniversary of the vesting start date and vest as to the remainder in equal monthly installments on the 36 subsequent monthly anniversaries of the vesting start date.

2. The shares underlying the option vested with respect to 25% of the shares on September 18, 2024 and vest as to the remainder in equal monthly installments on the 39 subsequent monthly anniversaries of December 18, 2023.

3. The shares underlying the option vest in equal monthly installments over a period of four years commencing from April 1, 2025.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Daniel Tardiff, PhD	10/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 3 filed for Camp4 (CAMP) report?

The Form 3 reports that Dr. Daniel Tardiff owns options covering 74,578 shares of common stock and no direct common stock holdings.

How are Dr. Tardiff's options structured?

Options include two tranches of 22,289 shares at $9.08, one tranche of 25,000 at $3.86, and one tranche of 5,000 at $3.53, with specified cliff and monthly vesting schedules.

When do the vesting schedules begin?

Vesting start dates include 09/18/2023 for certain tranches and a four-year monthly vesting commencing on 04/01/2025.

Does the filing show any exercises or sales?

No; the Form 3 only reports beneficial ownership via options and does not show any exercised or sold shares.

Will this filing trigger further disclosures?

If options are exercised or shares are sold, subsequent Form 4 filings would be required to report those transactions.